Event JSON
{
"id": "593a91d82a1ed465e086ce51ae4c46fcbd4bfc0a06f48e2e171895be700b8b0c",
"pubkey": "af947eb1ac2a94a86b48cbbda851396b8bcaa9aa59c9322e7c3da8264e0e9878",
"created_at": 1738486182,
"kind": 1,
"tags": [
[
"r",
"https://en.globes.co.il/en/article-analysts-remain-positive-on-teva-1001501006"
],
[
"subject",
"Analysts remain positive on Teva"
],
[
"published_at",
"1738493050"
],
[
"image",
"https://res.cloudinary.com/globes/image/upload/t_800X392/v1669041602/direct/Untitled-1_ngdpbe.jpg"
],
[
"p",
"af947eb1ac2a94a86b48cbbda851396b8bcaa9aa59c9322e7c3da8264e0e9878",
"wss://articles.layer3.news"
],
[
"imeta",
"url https://res.cloudinary.com/globes/image/upload/t_800X392/v1669041602/direct/Untitled-1_ngdpbe.jpg"
],
[
"t",
"Israel:perspective"
],
[
"summary",
"Teva's quarterly and annual financials sent its share price tumbling, but analysts stress the company's investment in its innovative pipeline and debt reduction. The company's guidance for 2025 includes non-GAAP earnings per share of $2.5 and free cash flow of $1.75 billion. Analysts from Bank of America, Piper Sandler, and Jefferies have revised their price targets, but most maintain positive ratings for the company."
]
],
"content": "nostr:nprofile1qyd8wumn8ghj7ctjw35kxmr9wvhxcctev4erxtnwv4mhxqpq4728avdv9222s66gew76s5fedw9u42d2t8ynytnu8k5zvnswnpuq7qxnev\nhttps://res.cloudinary.com/globes/image/upload/t_800X392/v1669041602/direct/Untitled-1_ngdpbe.jpg\nThe company's 2025 guidance sent its share price tumbling, but analysts stress its investment in its innovative pipeline and debt reduction.\nhttps://en.globes.co.il/en/article-analysts-remain-positive-on-teva-1001501006",
"sig": "55e8003d7a7a8e785326e87d1e03a345389f23d0094a0423e47005a77ea56a3d61bbb9246ba0c28bd0ca28798223af8d27c1721911a817947505ee05234a02f5"
}
